Home
Cancer Vaccines

SAE Media Group proudly presents the return of the 5th annual Cancer Vaccines conference to London in 2016. The use of cancer vaccines in combination with other cancer therapies is propelling the growth of the cancer vaccines market across the world. In addition factors such as the increasing number of people with cancer, rising public awareness of vaccines and the presence of promising late-stage pipeline candidate programs also enhance growth in the cancer vaccines market.*

The field of cancer vaccines is rapidly changing. Currently, different vaccination strategies such as conjugate-, DNA- and dendritic cell vaccines against tumor cells are being developed with increasing efficacy, SAE Media Group’s 5th annual Cancer Vaccines conference provides the perfect platform to delve further in to these strategies and engage in lively discussion within a concentrated and nice peer group.

A combination of cancer vaccines with pharmacotherapeutics remain the preferred choice to treat cancer. This not only increases the efficacy of the treatment but also helps improve the overall survival rate of patients.
SAE Media Group’s 5th annual Cancer Vaccines conference will heavily focus on the latest advances in combination therapies and personalised medicines.

The event will bring together leading industry professionals to discuss the immune checkpoint inhibitors and their use in vaccination, development and commercialisation of clinical trials and many more!
 

* http://www.fiercevaccines.com/press-releases/cancer-vaccines-market-growing-27-cagr-2019

 

Conference LEADER

keynote-img

Farzin Farzaneh

Professor of Molecular Medicine, Kings College London

Farzin studied at the universities of Aberdeen and Sussex,
followed by a number of fellowships (Beit, EMBO and MRC),
in UK and the Netherlands. He joined King’s College London
as a lecturer in Molecular Genetics in 1985, founded the
Molecular Genetics Unit in 1986 and was appointed the
founding Head of the Department of Molecular Genetics
in 1993. Farzin has published over 200 scientifi c papers and
two edited books on the Functional Analysis of the Genome
and Cancer Gene Therapy. He is a Qualifi ed Person (QP –
for cell and gene therapy based investigational medicinal
products) and has, since 2001 been the director of a GMP
facility at King’s, manufacturing products for clinical studies
in regenerative medicine and immune therapy of cancer.
He leads an active research group with a current funding
of over £2M per annum from Leukaemia Lymphoma
Research (now Bloodwise), CRUK, National Institute for
Health Research, UK Research Councils, as well as the
biotech and pharmaceutical industry.

FEATURED SPEAKERS

Kevin Pollock

Kevin Pollock

Senior Epidemiologist, Vaccine Preventable Diseases, Health Protection Scotland
Mustafa Diken

Mustafa Diken

Deputy Vice President Immunotherapies and Preclinical Research , Biontech RNA Pharmaceuticals GmbH

Andrew Gengos

President & CEO, ImmunoCellular Therapeutics Ltd
Andrew Gengos

Daejin Abidoye

Medical Director , Genentech, Inc.
Daejin  Abidoye

Elodie Belnoue

Head of Research, Amal Therapeutics
Elodie Belnoue

Farzin Farzaneh

Professor of Molecular Medicine, Kings College London
Farzin Farzaneh

Jeremy Fry

Director of Sales, ProImmune Ltd.
Jeremy Fry

John Castle

Senior Director, Bioinformatics, Agenus
John Castle

John Maudsley

CEO, Cancer Vaccines Ltd
John Maudsley

John Maudsley, Chief Executive Offi cer, Cancer Vaccines
John Maudsley has a background in cellular Immunology
having done his PhD with Avrion Mitchison FRS and Sir Marc
Feldmann at the Imperial Cancer Research Fund Tumour
Immunology Unit at University College London. He was a senior
research fellow at the University of Warwick and the founding
Chairman of the British Society’s West Midland Immunology
Group. In 1999 he founded Cancer Vaccines Ltd to develop
cell based allogeneic immunotherapies for treating cancer. He
is responsible for the company’s scientifi c and technological
direction. Cancer Vaccines has made considerable progress
in developing cell-based immunotherapies and is currently in
the early stages of a clinical trials programme. John Maudsley
is also involved in a company developing technology to
protect and immunise people against airborne infections with
particular potential in the event of a pandemic.

Kevin Pollock

Senior Epidemiologist, Vaccine Preventable Diseases, Health Protection Scotland
Kevin Pollock

Mads Hald Andersen

vice-director, professor, co-founder, Center for Cancer Immune Therapy (CCIT), RhoVac, IO Biotech.
Mads Hald Andersen

Mark Exley

VP Cellular Immunology , Agenus
Mark Exley

Mark Fogg

Immunology Group Leader, Abzena
Mark Fogg

Marnix Bosch

Chief Technical Officer, Northwest Biotherapeutics
Marnix Bosch

Matthias Miller

Project Manager, BioNTech AG
Matthias Miller

Mustafa Diken

Deputy Vice President Immunotherapies and Preclinical Research , Biontech RNA Pharmaceuticals GmbH
Mustafa Diken

Richard Harrop

Head of Clinical Analysis, Oxford BioMedica (U K) Limited
Richard Harrop

Roy Baynes

Senior Vice President & Head Global Clinical Development, Chief Medical Officer, MSD
Roy Baynes

Stephanie Traub

Biomarker Development Specialist at the Centre for Drug Development , Cancer Research UK
Stephanie Traub

sponsors

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

Overview of cancer therapy and the immune system

John Maudsley, CEO, Cancer Vaccines Ltd

clock

9:30

Role of cancer vaccines: potential effi cacy

John Maudsley, CEO, Cancer Vaccines Ltd

clock

10:00

Potential advantages and disadvantages of combination therapies with cancer vaccines

John Maudsley, CEO, Cancer Vaccines Ltd

• Potential benefi ts of combining with a second
cancer vaccine
• Potential benefi ts and risks of combination
with adjuvants, PKIs, CPIs, others

clock

10:45

Morning Coffee

clock

11:15

How to maximise vaccine effi cacy without combination with other therapies

John Maudsley, CEO, Cancer Vaccines Ltd

clock

11:45

Drawbacks and disadvantages of combining therapies

John Maudsley, CEO, Cancer Vaccines Ltd

clock

12:15

Discussion and Opportunities for collaboration with other cancer vaccine developers

John Maudsley, CEO, Cancer Vaccines Ltd

clock

12:45

Close of workshop

clock

13:30

Registration and Coffee

clock

14:00

Session 1 Strategies for the induction of cellular immunity

Farzin Farzaneh, Professor of Molecular Medicine, Kings College London

a. Adaptive cellular therapies, including CARs
and “armoured” CAR T cells
b. Active vaccination
c. Antibody based induction of cellular immune
responses

clock

15:00

Session 2 Identifi cation of Immunogenic Cancer Targets

Farzin Farzaneh, Professor of Molecular Medicine, Kings College London

a. Classical differentiation antigens, oncogenes,
etc.
b. Cancer and patient specifi c neo-antigen
mutations
c. Antibody based inhibition of negative immune
regulators

clock

15:40

Topic Heading 7

clock

16:00

Afternoon Tea

clock

16:30

Session 3 Therapeutic implications of the emerging immune oncology knowledge

Farzin Farzaneh, Professor of Molecular Medicine, Kings College London

a. Synthetic personalised neo-antigen
vaccination strategies
b. In vitro expansion of cancer specifi c T cells,
including “armoured” gene specifi c cytolytic
cells
c. Conversion of cancer specifi c immune
inhibitors into cancer specifi c immune
activators
d. Other new immune therapy strategies

clock

17:00

Closing Remarks

Farzin Farzaneh, Professor of Molecular Medicine, Kings College London

clock

17:30

Close of workshop

clock

8:30

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

Farzin Farzaneh

Farzin Farzaneh, Professor of Molecular Medicine, Kings College London

clock

9:10

Vaccination induced cellular immunity against cancer

Farzin Farzaneh

Farzin Farzaneh, Professor of Molecular Medicine, Kings College London

clock

10:30

Morning Coffee

clock

11:00

Case Study: Reaching the optimal design for the ICT-107 phase III dendritic cell immunotherapy trial for treating newly diagnosed glioblastoma

Andrew Gengos

Andrew Gengos, President & CEO, ImmunoCellular Therapeutics Ltd

• Phase II trial results and immune monitoring insights
• Learnings and improvements identifi ed to optimise Phase III
design
• Phase III execution
 

clock

11:40

Immunotherapy in cancer: Product design and in vitro assessment

Mark Fogg

Mark Fogg, Immunology Group Leader, Abzena

·          Immunogenicity and Immunotherapy
·          Epitope identification and manipulation
·          Immune profiling of immunotherapies
 

clock

12:20

Networking Lunch

clock

13:30

DCVax®: Novel personalised immune therapies for solid tumours

Marnix Bosch

Marnix Bosch, Chief Technical Officer, Northwest Biotherapeutics

• DCVax® is a fully personalised precision medicine, tailored to the individual patient and their tumour
• DCVax® mobilizes many active agents of the immune system to hit many targets on the cancer, unlike conventional cancer drugs and some other immune therapies, which generally use a single active agent to hit a single target on the cancer
• Full course of DCVax® doses can be manufactured in a single batch within about a week, and can be stored frozen until needed (including for years).

clock

14:10

Omics and big data for cancer vaccines

John Castle

John Castle, Senior Director, Bioinformatics, Agenus

• Immune checkpoint modulators show durable responses in cancer patients
• Omics platforms enable identifi cation of exploitable vaccine targets
• Omics platforms enable identifi cation of patients likely to benefit
• Next step is to combine checkpoint modulators with patient-specifi c vaccines for patient-optimised treatment

clock

14:50

Afternoon Tea

clock

15:20

Development of RNA-based vaccines and optimising their efficacy

Mustafa Diken

Mustafa Diken, Deputy Vice President Immunotherapies and Preclinical Research , Biontech RNA Pharmaceuticals GmbH

clock

16:00

Epitope identification and clinical immune monitoring

Jeremy Fry

Jeremy Fry, Director of Sales, ProImmune Ltd.

• Case studies detailing: Tandem mass spectrometry for T cell epitope identifi cation
• Practical learnings from the use of MHC multimers and ELISPOT in clinical immune monitoring
• Checkpoint blockade immune characterisation assays

clock

16:40

Chairman’s Closing Remarks and Close of Day One

Farzin Farzaneh

Farzin Farzaneh, Professor of Molecular Medicine, Kings College London

clock

8:30

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

Roy Baynes

Roy Baynes, Senior Vice President & Head Global Clinical Development, Chief Medical Officer, MSD

clock

9:10

Biomarker strategies for cancer vaccine trials

Stephanie Traub

Stephanie Traub, Biomarker Development Specialist at the Centre for Drug Development , Cancer Research UK

clock

9:50

The impact of the HPV vaccine in Scotland - a changing landscape

Kevin Pollock

Kevin Pollock, Senior Epidemiologist, Vaccine Preventable Diseases, Health Protection Scotland

• Uptake of HPV vaccine approximates 90% for all doses in young Scottish women
• Vaccine associated with signifi cant reductions in HPV 16, 18 and other oncogenic types
• Vaccine associated with signifi cant reductions in all grades of cervical intraepithelial neoplasia
• Herd protection vs HPV 16 and 18 in those who are unimmunised

clock

10:30

Morning Coffee

clock

11:00

PD-1 Blockade: A broad spectrum anticancer therapeutic

Roy Baynes

Roy Baynes, Senior Vice President & Head Global Clinical Development, Chief Medical Officer, MSD

clock

11:40

Irrigating the immune desert: Historical perspective and path forward in GU malignancies

Daejin  Abidoye

Daejin Abidoye , Medical Director , Genentech, Inc.

• GU Malignancies have become an ideal platform for cancer immunotherapy development
• A minority of patients respond to monotherapy checkpoint inhibition
• Gene expression profi ling of responders and non-responders identifies potential resistance mechanisms
• Personalising immunotherapy is necessary to optimize selection of combination therapy to improve response rates and salvage disease progression

clock

12:20

Networking Lunch

clock

13:30

Case Study: Clinical development of TroVax (MVA-5T4) and identifi cation of biomarkers predictive of response

Richard Harrop

Richard Harrop, Head of Clinical Analysis, Oxford BioMedica (U K) Limited

• Cancer vaccines are believed to have a delayed therapeutic effect, therefore an early marker of effi cacy would be valuable
• Few immunotherapy compounds have demonstrated a clear link between the predicted mode of action of the product and clinical benefit
• Data from a phase III trial of TroVax in renal cancer patients has enabled a detailed investigation of early predictors of treatment benefit and demonstrated that antibodies, induced
by vaccination, against the tumour antigen 5T4 correlated strongly with enhanced patient survival
• We describe the development of a simple biomarker using pre-treatment factors which are readily measured in patients. The biomarker showed a significant correlation with the magnitude of the induced 5T4 antibody response and enhanced survival

clock

14:10

Development and optimisation of self-adjuvanting protein vaccine

Elodie Belnoue

Elodie Belnoue, Head of Research, Amal Therapeutics

clock

14:50

Afternoon Tea

clock

15:20

Activation of anti-regulatory T cells: A novel immuno-oncology approach

Mads Hald Andersen

Mads Hald Andersen, vice-director, professor, co-founder, Center for Cancer Immune Therapy (CCIT), RhoVac, IO Biotech.

clock

16:00

IVAC® MUTANOME – A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma

Matthias Miller

Matthias Miller, Project Manager, BioNTech AG

clock

16:40

Chairman’s Closing Remarks and Close of Day Two

Roy Baynes

Roy Baynes, Senior Vice President & Head Global Clinical Development, Chief Medical Officer, MSD


President & CEO
ImmunoCellular Therapeutics Ltd
Medical Director
Genentech, Inc.
Head of Research
Amal Therapeutics
Professor of Molecular Medicine
Kings College London
Director of Sales
ProImmune Ltd.
Senior Director, Bioinformatics
Agenus
CEO
Cancer Vaccines Ltd
Senior Epidemiologist, Vaccine Preventable Diseases
Health Protection Scotland
vice-director, professor, co-founder
Center for Cancer Immune Therapy (CCIT), RhoVac, IO Biotech.
VP Cellular Immunology
Agenus
Immunology Group Leader
Abzena
Chief Technical Officer
Northwest Biotherapeutics
Project Manager
BioNTech AG
Deputy Vice President Immunotherapies and Preclinical Research
Biontech RNA Pharmaceuticals GmbH
Head of Clinical Analysis
Oxford BioMedica (U K) Limited
Senior Vice President & Head Global Clinical Development, Chief Medical Officer
MSD
Biomarker Development Specialist at the Centre for Drug Development
Cancer Research UK

Sponsors and Exhibitors

Official Media Partner

Official Publication

Official Online Media Partners

Supporters

Workshops

Cancer vaccines & combination therapies

Cancer vaccines & combination therapies

Holiday Inn Kensington Forum
20 September 2016
London, United Kingdom

Active Immune Therapy of Cancer – Emerging Strategies

Active Immune Therapy of Cancer – Emerging Strategies

Holiday Inn Kensington Forum
20 September 2016
London, United Kingdom

An Interview with BioNTech AG

Download

An Interview with Daejin Abidoye, Medical Director from Roche-Genentech

Download

An Interview with Mark Fogg, Head of Immunology, Abzena

Download

An Interview With NHS, Health Protection Scotland

Download

Interview with Biontech RNA Pharmaceuitcals

Download

Sponsors and Exhibitors


Abzena

Sponsors and Exhibitors
http://www.abzena.com

Abzena offers a suite of complementary services and technologies. Its range of technologies include immunogenicity assessment, antibody drug conjugation, protein engineering, PEGylation, cell line development , GMP manufacturing and a range of bespoke assays to enables the development of better biopharmaceuticals which will have a greater chance of reaching the market.


Northwest Biotherapeutics

Sponsors and Exhibitors
http://www.nwbio.com/

"The Company (NWBio) has received some shareholder inquiries about whether the Company will be presenting at the SMi conference in London on September 27-28, 2017. While anticipating the disclosure of interim blinded data from NWBio’s Phase III trial of DCVax®-L for Glioblastoma, NWBio will not be presenting at this year’s SMi conference.”

NWBio is developing DCVax® dendritic cell-based therapeutic vaccines. The Company’s DCVax®-L for resectable solid tumors is in a 331-patient Phase III trial for newly diagnosed GBM and Phase II trials in combination with checkpoint inhibitor drugs are planned. The Company’s DCVax®-Direct for inoperable solid tumors has completed a 40-patient Phase I trial for diverse cancers; various Phase II trials are planned.


Media Partners


Cancer Biomarkers (CBM)

Official Media Partner
http://www.iospress.nl/journal/cancer-biomarkers/

Concentrating on molecular biomarkers in cancer research, Cancer Biomarkers publishes original research findings (and reviews solicited by the editor) on the subject of the identification of markers associated with the disease processes whether or not they are an integral part of the pathological lesion. The disease markers may include, but are not limited to, genomic, epigenomic, proteomics, cellular and morphologic, and genetic factors predisposing to the disease or indicating the occurrence of the disease. Manuscripts on these factors or biomarkers, either in altered forms, abnormal concentrations or with abnormal tissue distribution leading to disease causation will be accepted.


Journal of Chemotherapy

Official Media Partner
http://www.maneyonline.com/loi/joc

Journal of Chemotherapy is an international multidisciplinary journal committed to the rapid publication of high quality, peer-reviewed, original research. The Journal publishes original experimental and clinical research articles, reviews, brief communications and letters on all aspects of antimicrobial, anticancer and immunomodulating chemotherapy. Review articles by authoritative experts on new trends and developments in the relevant fields are also invited.


DNAvaccine.com

Official Media Partner
http://www.dnavaccine.com/

The DNA Vaccine Web was launched in 1995 by Robert Whalen. This eventually became DNAvaccine.com and has always been a central resource to the fields of DNA vaccinology and non-viral gene transfer. DNAvaccine.com has helped to teach people about nucleic acid vaccines, find funding opportunities, define collaborative networks, launch new companies, and much more.


BioChem Adda

Official Media Partner
https://www.biochemadda.com/

BioChem Adda is a Not-just-for-Profit organization which aims to bring out the most reliable and transparent information about everything related to jobs, careers, education, news, articles, and events from the field of BioSciences and Chemistry!

Media Partners


International Journal of Biotechnology

Official Publication
http://www.inderscience.com/ijbt

IJBT provides an international forum and refereed authoritative source of information in the field of Biotechnology and Biotechnics, with emphasis on management and economics, as well as the political and social issues. It aims to disseminate knowledge, provide a learned reference in the field, and establish channels of communication between academic and research experts, policy makers and executives in industry, commerce and investment institutions.


International Journal of Bioinformatics Research and Applications

Official Publication
http://www.inderscience.com/ijbra

Bioinformatics is an interdisciplinary research field that combines biology, computer science, mathematics and statistics into a broad-based field that will have profound impacts on all fields of biology. The emphasis of IJBRA is on basic bioinformatics research methods, tool development, performance evaluation and their applications in biology. IJBRA addresses the most innovative developments, research issues and solutions in bioinformatics and computational biology and their applications.

Media Partners


The Pharma Letter

Official Online Media Partners
http://www.thepharmaletter.com/

The Pharma Letter provides subscribers with daily, up-to-date news, business intelligence, comment and analysis for the pharmaceutical, biotechnology and generics sectors of the health care industry, backed by a team of respected writers with many years of experience in the field.

Media Partners


SelectScience

Supporters
http://www.selectscience.net/register?utm_source=Media-Partner&utm_medium=Website&utm_campaign=SMI

SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover the latest drug discovery and development technologies, products and techniques with product reviews, videos, application notes and news articles. Become a member for free today.


American Pharmaceutical Review

Supporters
http://www.americanpharmaceuticalreview.com

Start receiving your free copy today. American Pharmaceutical Review is a review of the drug pipeline from the late discovery phase through manufacturing. American Pharmaceutical Review prides itself on having the most relevant, unbiased and informative editorial in the industry. You will find that all of our editorial is highly technical and written by government agencies, consultants, academics, and large pharmaceuticals companies. American Pharmaceutical Review covers several key topics that are important to drug production:Separations and purification, Drug Delivery, Biopharmaceutical Processing, Biopharmaceutical Development, Formulation development, Manufacturing, Microbiology, Instrumentation, Spectroscopy


PharmaVOICE

Supporters
http://www.pharmavoice.com

PharmaVOICE magazine, and its supporting VIEW publications, provide commentary about the challenges and trends impacting the life-sciences industry, covering a range of issues from molecule through market. PharmaVOICE's more than 41,000 U.S.-based subscribers are also kept abreast of the latest trends through additional media resources, including WebSeminars, Podcasts, Videocasts, and White Papers.


Gate2Biotech

Supporters
http://www.gate2biotech.com

Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.


Pharmiweb

Supporters
http://www.pharmiweb.com

Established in October 2003, PharmiWeb Solutions is an energetic, innovative provider of web-based solutions for the pharmaceutical sector, with customers such as AstraZeneca, Roche, Servier Laboratories, and Merck With solutions in three key areas: Online Publishing, e-Business and Mobile Computing, we deliver connectivity – between people and applications – unlocking islands of data and knowledge. We own some of the sector’s most innovative Online Publications: PharmiWeb.com, HospitalPharma.com and Detail-Direct.com. We are actively developing solutions for Mobile Computing platforms. For example, our PharmiTabTM e-pharmacy solution runs real-time patient data and prescribing transactions in a busy hospital environment, on a TabletPC, wireless client/server platform. e-Business solutions range from e-Detailing, to Online Market Research, all designed to increase reach, increase sales, and to reduce administration and costs.


Drug Development Technology

Supporters
http://www.drugdevelopment-technology.com

Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


Thomson Reuters

Supporters
http://thomsonreuters.com/products_services/science/

Thomson Reuters is the leading source of intelligent information for professionals around the world. We provide essential information to keep you in touch with the rapidly-changing pharmaceutical and chemical markets, expert services to help you make informed, early decisions, and intuitive technology to manage and support your discovery and development activities. Our products give you the intelligence, tools and expertise to help you optimize your IP portfolio, monitor industry developments, identify licensing and partnering opportunities, deliver successful regulatory submissions, and support your scientific messaging, marketing, product positioning, and awareness campaigns.


Samedan

Supporters
http://www.samedanltd.com/magazine/13.

International Clinical Trials (ICT) is a quarterly magazine edited by Dr Graham Hughes, and written by specialists at the forefront of clinical research. ICT’s coverage of operational developments ranges from adaptive designs in early phase trials through to post marketing research. ICT’s targeted readership consists of key decision makers across the pharmaceutical and biotech industries, along with contract partners and consultants. The magazine is distributed to pharmaceutical professionals in Europe and North America, and is accessed globally online. Read the latest issues, explore the ICT archive and subscribe at www.samedanltd.com/magazine/13.


Biosave

Supporters
http://www.Biosave.com

Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.


EBR

Supporters
http://www.samedanltd.com

European BioPharmaceutical Review (EBR) provides a dedicated platform of communication and information for the biopharmaceutical market across Europe, North America and the rest of the world. Each quarterly issue, 10,500 copies of the magazine are distributed to our specially-targeted readership with articles on the hottest topics written by eminent commentators from the biotech scene. www.samedanltd.com


International Pharmaceutical Industry

Supporters
http://www.ipimediaworld.com

IPI gives you an insight into all areas of Biopharm, Medical, Pharmaceutical and Healthcare. IPI provides a proven supportive means of communication to the Pharmaceutical, Bio Pharmaceutical, Nutraceutical and Medical Devices industry, incorporating the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies.


European Biotechnology Network

Supporters
http://european-biotechnology.net/

The European Biotechnology Network is dedicated to facilitating co-operation between professionals in biotechnology and the life sciences all over Europe. The non-profit organisation brings research groups, universities, SMEs, large companies and indeed all actors in biotechnology together to build and deliver partnerships.


GBI

Supporters
http://www.gbihealth.com/

GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.


Inderscience Publishers

Supporters
http://www.inderscience.com

Inderscience is a dynamic, leading, independent journal publisher. The company disseminates the latest research across the broad fields of science, engineering and technology; management, public and business administration; environment, ecological economics and sustainable development; computing, ICT and internet/web services, and related areas. Inderscience offers over 35 years' experience in publishing and has succeeded in building a substantial collection approaching 400 high-quality peer-reviewed international research journals in both online and print formats. We offer a variety of ways to keep up-to-date with the latest published leading-edge research while our online collection represents a fully-searchable digital archive of around 60,000 articles.


Pharmavision

Supporters
http://www.pharmavision.co.uk

PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


BioPharm Insight

Supporters
http://www.biopharminsight.com

BioPharm Insight is your definitive guide to the global life sciences community. Subscribers take action on forward-looking intelligence uncovered by an independent team of investigative journalists, and make strategic business decisions using the most comprehensive and powerful real-time database of market analytics and key contacts. Featuring an intuitive online interface and exclusive Active IntelT relational content technology, BioPharm Insight provides an unrivaled capability to segment and analyze the industry with detailed and searchable profiles.


Bentham Science

Supporters
http://www.benthamscience.com/

Bentham Science Publishers is a major STM journal publisher of 130 plus print and online journal. Out of these, 40 journals have already registered good IMPACT FACTORS as per Journal Citation Reports® 2017. These titles have extensive readership mostly in Europe and North America. For a detailed profile please visit our website at http://www.benthamscience.com. Besides, Bentham Science publishes eBooks in all areas of Science, Technology and Medicine. Our eBooks provide professionals, academicians, corporate researchers, graduates and undergraduates worldwide with the most current information in their subject areas of interest. Our eBooks are also available in the ePub and Kindle formats besides the PDF edition here http://ebooks.benthamscience.com/. Bentham is offering attendees of this conference discounts on its publication. For more information click here


Copybook - Pharmaceutical

Supporters
http://www.copybook.com/pharmaceutical

Copybook is a global business network with many pharmaceutical events, exhibitions and seminars. We encourage business-to-business transactions and work tirelessly to gain our customers new business contracts worldwide. You can add events, companies and associations for free. When you are a member, you can add your company to the events listed in order to encourage other visitors to arrange meetings and appointments at those events to facilitate new business contracts. Want to see how we can increase your business network and transactions? SIGN UP FOR FREE today! Copybook – Your Global Business Network


Labsave

Supporters
http://www.labsave.com

Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/


Drug Discovery Today

Supporters
http://www.drugdiscoverytoday.com/

Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.


Swiss Biotech Association

Supporters
http://www.swissbiotech.org/

The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


IOS Press

Supporters
http://www.iospress.nl

IOS Press publishes about 120 new books and 100 international journals each year covering topics ranging from computer science and mathematics to medicine and the natural sciences. All titles in this catalogue are available online as well as in print. Many titles are covered in the most important abstracting databases, such as Thomson Reuters / ISI, MEDLINE and SciVerse Scopus. Headquartered in Amsterdam with satellite offices in the USA, Germany, India and China, IOS Press has established several strategic co-publishing initiatives. Notable acquisitions included Delft University Press in 2005 and Millpress Science Publishers in 2008. IOS Press journals are available through the highly-regarded MetaPress platform.


Medical News Today

Supporters
http://www.medicalnewstoday.com

Medical News Today is the largest independent medical and health news site on the web - with over 10,000,000 monthly unique users it is ranked number one for medical news on all major search engines. Medical News Today is used by pharmaceutical, biotech and health organizations, advertising agencies, PR companies and vertical ad networks to deliver targeted campaigns to HCPs, patients and caregivers. To find out how Medical News Today can help you to reach the right audience contact peter@medicalnewstoday.com or visit www.medicalnewstoday.com.


One Nucleus

Supporters
http://www.onenucleus.com

Established in May 2010, One Nucleus is the result of the merger of ERBI and London Biotechnology Network. One Nucleus is a not-for-profit membership organisation for international life science and healthcare companies and the largest of its kind in Europe. The company is based in Cambridge UK and London, at the heart of Europe's largest cluster. The 470 members include pharmaceutical, biotech, medical device and diagnostic companies and associated technical and commercial Service Providers.


Technology Networks

Supporters
http://go.technologynetworks.com/subscribe-to-newsletters

Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


Labhoo

Supporters
http://www.labhoo.com



Drug Target Review

Supporters
http://www.drugtargetreview.com

Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.


Pharmaceutical Technology

Supporters
http://www.pharmaceutical-technology.com

Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


Absave

Supporters
http://www.absave.com

Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


Pharmaceutical Outsourcing

Supporters
http://www.pharmoutsourcing.com

Pharmaceutical Outsourcing, the journal dedicated to pharmaceutical and biopharmaceutical contract services. With regular sections on contract manufacturing, contract research, contract packaging, formulation/development services, contract analytical testing, APIs, stability testing, clinical research and other areas, we bring the most complete coverage of trends and issues in the industry to our 15,000 readers in North America.


Taylor & Francis Group

Supporters
http://bit.ly/TF-Med

As one of the world’s leading publishers of scholarly journals, books, eBooks, reference works, and databases, Taylor & Francis Group partners with researchers, scholarly societies, universities, and libraries worldwide to bring knowledge to life.


Pharmalicensing

Supporters
http://www.pharmalicensing.com

Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc.


CanBiotech

Supporters
http://www.canbiotech.com

CanBiotech - A Portal and B2B Outsourcing Marketplace for the Biotech and Pharmaceutical Industry. The Marketplace features the Outsourcing Services Showcase; the Portal features our biopharmaceutical and venture capital directories and databases. Publications include the BioMedical Outsourcing Report and the Bio Outsourcing Asia© Publication.


Pharmacircle

Supporters
http://www.pharmacircle.com

PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


Farmavita

Supporters
https://farmavitar.com

FarmavitaR+ is the professional network of experts and service providers. Network is gathering local consultants from 90 countries in Europe, Asia, North America, Latin America, Australia and Africa. Management of international, multi-centre projects is our core competence. FarmavitaR+ is providing solutions related to pharmaceutical, medical device, food supplement and cosmetic products. Scope of services is related to solutions for product development, quality assurance, clinical trials, product registration, portfolio analysis, lifecycle management, vigilance/risk management, pricing/reimbursing, market access and promotional compliance. FarmavitaR+ is brand name of Farmavita Regulanet Ltd. Visit https://farmavitar.com for more information. Outsource anything you can think of!

Holiday Inn Kensington Forum

97 Cromwell Road
London SW7 4DN
United Kingdom

Holiday Inn Kensington Forum

Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

HOTEL BOOKING FORM

Title

SubTitle
speaker image

Content


Title


Description

Download

Title


Description

Download

Title


Description


Download


WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

Event Title

Headline

Text
Read More

I would like to speak at an event

I would like to attend an event

Group Booking

Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

I would like to sponsor/exhibit at an event

SIGN UP OR LOGIN

Sign up
Forgotten Password?

Contact SAE Media Group

UK Office
Opening Hours: 9.00 - 17.30 (local time)
SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smgconferences.com Email: events@saemediagroup.com
Registered in England - SMi Group Ltd trading as SAE Media Group




Forgotten Password

Please enter the email address you registered with. We will email you a new password.

Thank you for visiting our event

If you would like to receive further information about our events, please fill out the information below.

By ticking above you are consenting to receive information by email from SAE Media Group.
Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

Fill in your details to download the brochure

By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.